期刊文献+

依折麦布联合他汀类药物对肾病作用的研究进展 被引量:6

原文传递
导出
摘要 高脂血症与肾脏疾病关系密切,它既是其常见的临床表现,又参与其发生和进展。血脂异常作为肾小球硬化发生和进展的独立危险因素可损伤血管内皮细胞,引起炎性反应,促进肾脏动脉粥样硬化发生,并对肾脏细胞具有直接毒性,加速慢性肾脏疾病(CKD)的进展。肾功能恶化又会加重高脂血症,
出处 《中国医师进修杂志》 2013年第25期73-75,共3页 Chinese Journal of Postgraduates of Medicine
基金 黑龙江省科技计划(QCOSC13)
  • 相关文献

参考文献1

二级参考文献10

  • 1Raúl J Andrade,Mercedes Robles,Alejandra Fernández-Castaer,Susana López-Ortega,M Carmen López-Vega,M Isabel Lucena.Assessment of drug-induced hepatotoxicity in clinical practice: A challenge for gastroenterologists[J].World Journal of Gastroenterology,2007,13(3):329-340. 被引量:18
  • 2Qiang Liu,Hillel Tobias,Lydia M. Petrovic.Drug-Induced Liver Injury Associated with Ezetimibe Therapy[J].Digestive Diseases and Sciences.2007(2)
  • 3Jackevicius CA,Tu JV,Ross JS,Ko DT,Krumholz HM.Use of ezetimibe in the United States and Canada[].The New England Journal of Medicine.2008
  • 4Bhardwaj SS,Chalasani N.Lipid-lowering agents that cause drug-induced hepatotoxicity[].Clinics in Liver Disease.2007
  • 5Maddrey WC.Drug-induced hepatotoxicity: 2005[].Journal of Clinical Gastroenterology.2005
  • 6Stolk MF,Becx MC,Kuypers KC,Seldenrijk CA.Severe hepatic side effects of ezetimibe[].Clinics in Gastroenterology.2006
  • 7Liu Q,Tobias H,Petrovic LM.Drug-induced liver injury associated with ezetimibe therapy[].Digestive Diseases and Sciences.2007
  • 8Sabate M,Ibanez L,Perez E,Vidal X,Buti M,Xiol X,Mas A,Guarner C,Forne M,Sola R,Castellote J,Rigau J,Laporte JR.Risk of acute liver injury associated with the use of drugs: a multicentre population survey[].Alimentary Pharmacology and Therapeutics.2007
  • 9Fernando Civeira and International Panel on Management of Familial Hypercholesterolemia.Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia[].Atherosclerosis.2004
  • 10van Heyningen C.Drug-induced acute autoimmune hepa-titis during combination therapy with atorvastatin and ezetimibe[].Annals of Clinical Biochemistry.2005

共引文献2

同被引文献54

  • 1中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5219
  • 2Fatica RA, Dennis VW. Cardiovascular mortality in chronic renal failure., hyperphosphatemia, coronary calcification, and the role of phosphate binders[J]. Cleve Clin J IVied, 2002, 69 (Suppl 3) : S21-S27.
  • 3Catapano AL, Reiner Z,DeBacker G, et al. ESC/EAS Guide- lines for the management of dyslipidaemias The TaskForce for the management of dyslipidaemias of the European Society of Cardiology(ESC) and the European Atherosclerosis Society (EAS)[J]. Atherosclerosis, 2011, 217(1): 3-46.
  • 4Balaskas EV, Bamihas GI, Tourkantonis A. Management of lipid abnomalities in patients with CAPD[J]. Perit Dial Int, 1997, 17: 308-309.
  • 5Little J, Phillips L,Russel L, et al. Longitudinal lipid profiles on CAPD: their relationship to weight gain, comorbidity, and dialysis factor[J]. J Am Soc Nephrol, 1998, 9(10): 1931- 1939.
  • 6Daum U, Leren TP,Langer C, et al. Multiple dysfunctions of two apolip oprotein A-I (R160L) also and apoA-I (P165R), that are associated with hypoalphali poproteinemia in heterozy- gous carriers[J]. J Lipid Res, 1999, 40(3): 486-494.
  • 7Delarve J, Maingourd C,Couet C, et al. Effect of oral glucose on intermediary metabolism in continuous ambulatory perito- neal dialysis patients versus healthy subjects[J3. Perit Dial Int, 1998, 18(5): 505-511.
  • 8Goren A, Stankiewicz H,Goldstein R, et al. Fishoil treatment of hyper lipidemia in children and adolescents receiving renal replacement therapy[J]. Pediatrics, 1991, 88: 265-268.
  • 9Cholesterol Treatment Trialists" Ctt Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials[J]. Lancet, 2012, 380(9841) ; 581- 590.
  • 10Kones IL Primary prevention of coronary heart disease: inte- gration of new data, evol;Jing views, revised goals, and role of rosuvasatin in management[J]. Drug Des DeVel Ther, 2011, 5 : 325-380.

引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部